The results of the test for assessing the manifestation of side effects of antipsychotic drugs, which are characterized by abnormal involuntary movements
- VernacularTitle:Солиорлын эсрэг эмийн гаж нөлөөний илрэлийг өөрийгөө хянах боломжгүйгээр хийдэг эмгэг хөдөлгөөнийг үнэлэх сорилоор үнэлсэн дүн
- Author:
Khishigsuren Z
1
;
Tergel Kh
1
;
Khongorzul E
1
;
Elik M
1
Author Information
1. Department of Mental Health, School of Medicine, MNUMS
- Publication Type:Journal Article
- Keywords:
Schizophrenia;
Parkinson-like syndrome;
Assessment;
Side effect management;
Dependance
- From:
Mongolian Journal of Health Sciences
2025;85(1):125-129
- CountryMongolia
- Language:Mongolian
-
Abstract:
Background:According to WHO research, there are approximately 24 million people living with schizophrenia worldwide and schizophrenia is characterized by a combination of psychotic and non-psychotic symptoms. Since the cause of
the disease is not fully understood, antipsychotic medications are used as symptomatic treatment. According to the 2022
statistics of the NCMH, 718 people with schizophrenia are being treated under active surveillance in Mongolia. The reason for conducting this study is that the manifestation of drug side effects resulting movement disorders in patients with
schizophrenia, which has not been studied in Mongolia.
Aim:To investigate the relationship between adherence of medication regimen and abnormal involuntary movements in
patients with schizophrenia.
Materials and Method:The study was conducted using a descriptive method, cross-sectional design, purposive sampling with the questionnaire and standardized tests. Ethical approval for this study was approved by the NCMH (№3/77
30th of January, 2023) and Research Ethics Review Committee of MNUMS (№2023/3-02). Each participant was asked to
complete 5 groups of 36 questionnaires, and standard tests were used to assess patients’ adherence to medication regimens
(Morisky scale) and abnormal involuntary movement scale (AIMS). The study was conducted between March and August
2023, and the results were summarized and analyzed using STATA 14 software.
Results: The study included 209 patients with schizophrenia, aged 18-79 years, of whom 47.4% (n=99) were male
and 52.6% (n=110) were female (p=0.21). Of the participants, 28.2% (n=59) had less than secondary education, 76.5%
(n=160) were unmarried, and 85.2% (n=178) had a disability due to mental health. 32.5% (n=68) of the patients with
schizophrenia in the study used a combination of typical and atypical medications, and the most commonly used antipsychotic drugs were haloperidol (30.6%), chlorpromazine (26.8%), levomepromazine (25.8%), risperidone (24.4%),
and quetiapine (21.1%). 1.4% (n=3) of the patients had good, 52.6% (n=110) had moderate, and 45.9% (n=96) had poor
adherence to the medication regimen (Cronbach’s α=0.781). However, according to the results of the test for assessing
abnormal involuntary that are performed without self-control, 49.76% (n=104) responded that they felt more sensitive to
facial and oral movements, and 44.5% (n=93) to limb movements. The patients’ adherence to the medication regimen was
statistically significant with facial and oral movements (n=104; p=0.036) and general body movement disorders (n=94;
p=0.05).
Conclusion:32.5% of patients with schizophrenia were taking typical and atypical antipsychotics, and 45.9% had poor
adherence to medication regimens and were more likely to exhibit clinical forms of abnormal involuntary movements,
including facial (p=0.036) and general movement disorders (p=0.05).
- Full text:2025052715254619625125-129.pdf
